Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Deadly Drug-Resistant Strain of Escherichia coli Emerged as a Single Genetic Clone

By BiotechDaily International staff writers
Posted on 02 Jan 2014
Image: Colonies of Escherichia coli growing in a laboratory culture (Photo courtesy of the CDC - Centers for Disease Control and Prevention).
Image: Colonies of Escherichia coli growing in a laboratory culture (Photo courtesy of the CDC - Centers for Disease Control and Prevention).
Molecular microbiologists working with advanced genomic research tools have shown that an extremely virulent and drug-resistant strain of Escherichia coli appeared about 10 years ago following mutations in two genes.

Previous studies on the H30-Rx clone of the ST131 strain of E. coli using pulsed-field gel electrophoresis (PFGE) had indicated that characteristics such as propensity for extraintestinal infections, fluoroquinolone resistance, and extended-spectrum beta-lactamase (ESBL) production had arisen as a series of independent genetic events. If this conclusion were correct, it would suggest that the existence of many different intermediate strains would exist with multiple pathways for evading the immune system and medical treatment.

However, in a new study published in the December 17, 2013, edition of the journal mBio, investigators at George Washington University School of Public Health (Washington DC, USA) and their colleagues at the University of Minnesota (Minneapolis, USA) used the advanced genomic technique, whole-genome sequencing, to reconstruct the evolutionary history of the ST131 clone. The investigators analyzed the genomes of samples of E. coli collected from patients and animals in five countries over the 44-year period, 1967–2011.

They found that fluoroquinolone resistance was confined almost entirely to a single, rapidly expanding ST131 subclone, designated H30-R. This clone, which was fully resistant to the drug ciprofloxacin, soon morphed into a new clone called H30-Rx, which was resistant to several extended-spectrum antibiotics, such as third-generation cephalosporins.

The investigators believe that the clonal nature of H30-Rx may provide opportunities for vaccine or transmission prevention-based control strategies, which could gain importance as H30-Rx and other extraintestinal pathogenic E. coli subclones become resistant to an increasing number of antibiotics.

"This strain of E. coli spreads from person to person and seems to be particularly virulent," said contributing author Dr. James R. Johnson, professor of medicine at the University of Minnesota. "This study might help us develop better tools to identify, stop or prevent its spread by finding better ways to block the transmission of the superbug, or by finding a diagnostic test that would help doctors identify such an infection early on, before it might have the chance to turn lethal."

Related Links:

George Washington University School of Public Health
University of Minnesota



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: The nano-cocoon drug delivery system is biocompatible, specifically targets cancer cells, can carry a large drug load, and releases the drugs very quickly once inside the cancer cell. Ligands on the surface of the \"cocoon\" trick cancer cells into consuming it. Enzymes (the “worms\" in this image) inside the cocoon are unleashed once inside the cell, destroying the cocoon and releasing anticancer drugs into the cell (Photo courtesy of Dr. Zhen Gu, North Carolina State University).

Novel Anticancer Drug Delivery System Utilizes DNA-Based Nanocapsules

A novel DNA-based drug delivery system minimizes damage to normal tissues by utilizing the acidic microenvironment inside cancer cells to trigger the directed release of the anticancer drug doxorubicin (DOX).... Read more

Lab Technologies

view channel

Experimental Physicists Find Clues into How Radiotherapy Kills Cancer Cells

A new discovery in experimental physics has implications for a better determination of the process in which radiotherapy destroys cancer cells. Dr. Jason Greenwood from Queen’s University Belfast (Ireland) Center for Plasma Physics collaborated with scientists from Italy and Spain on the work on electrons, and published... Read more

Business

view channel

Interest in Commercial Applications for Proteomics Continues to Grow

Increasing interest in the field of proteomics has led to a series of agreements between private proteomic companies and academic institutions as well as deals between pharmaceutical companies and novel proteomics innovator biotech companies. Proteomics is the study of the structure and function of proteins.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.